Neuropsychiatry

Johnson & Johnson Neuropsychiatry Pipeline Advances with New APA/ASCP Data

By Clinical Trials & Data Desk
11 May 2026

Johnson & Johnson reinforces its leadership in neuropsychiatry, presenting pivotal data for seltorexant and aticaprant at the 2024 APA and ASCP meetings.

Tag: Neuropsychiatry

Johnson & Johnson Neuropsychiatry Pipeline Advances with New APA/ASCP Data

Areas Covered

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement